NABIHEAL Antimicrobial Nanostructured Biomaterials for Complex Wound Healing
- Coordinator
- Consorcio Centro De Investigacion Biomedica En Red M.p., Spain
- Runs
- 1 January 2023 to 31 December 2026
- Status
- Running
- EU funding
- €5.0m
- Total cost
- €5.0m
- Partners
- 15 organisations in 7 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101092269
What the project is doing
In the project's own words, from its summary on CORDIS.
Complex wounds are a global health problem with significant impact on the health care economy. In developed countries alone, they impact the quality of life of more than 2% of total population. Complex wounds, including chronic wounds or major burns, are highly susceptible to microbial infection and biofilm formation, and difficult to treat. Moreover, silver is a widely used metal in antimicrobial products to treat wound infections.
However, silver-based products are expensive, and show several drawbacks due to costs, as well as environmental and safety concerns. The NABIHEAL project will develop multifunctional biomaterials, from proof-of-concept (TRL 3) to the preclinical regulatory stage (TRL 5), to improve wound management. The resulting biomaterials will enable affordable treatment of wound infections or prevention of complications during all phases of the wound healing process.
In the short and medium term, NABIHEAL will develop at least two innovative multifunctional wound-healing biomaterials, using affordable EU-based manufacturing technologies. In the long term, NABIHEAL could become a game-changing alternative to silver in wound-healing dressings. A consortium comprising 5 SMEs and 9 academic institutions, with expertise in wound healing product development, evaluation and commercialization, nanotechnology, safety, and regulatory affairs, will join forces to address these ambitious objectives.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Consorcio Centro De Investigacion Biomedica En Red M.p. | Madrid | Spain | Coordinator |
| Bionanonet Forschungsgesellschaft Mbh | Graz | Austria | Participant |
| Charite - Universitaetsmedizin Berlin | Berlin | Germany | Participant |
| Mybiotech GmbH | Uberherrn | Germany | Participant |
| Aarhus Universitet | Aarhus C | Denmark | Participant |
| Agencia Estatal Consejo Superior De Investigaciones Cientificas | Madrid | Spain | Third party |
| Asphalion SL | Barcelona | Spain | Participant |
| Bioiberica Sau | Palafolls | Spain | Participant |
| Histocell SL | Derio Bizkaia | Spain | Participant |
| Nanomol Technologies SL | Cerdanyola Del Valles | Spain | Participant |
| Universidad De Cantabria | Santander | Spain | Third party |
| Universidad De Granada | Granada | Spain | Participant |
| Institut Za Medicinska Istrazivanja I Medicinu Rada | Zagreb | Croatia | Participant |
| Technion - Israel Institute of Technology | Haifa | Israel | Participant |
| Univerza V Mariboru | Maribor | Slovenia | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI